论文部分内容阅读
目的观察头孢哌酮舒巴坦钠治疗社区获得性肺炎(CAP)的临床效果。方法将80例CAP患者随机分为观察组和对照组各40例。观察组应用头孢哌酮舒巴坦钠治疗,对照组应用左氧氟沙星治疗,比较2组临床疗效、症状体征改善情况和致病菌清除率。结果治疗7d后,观察组总有效率为95.00%明显高于对照组的92.25%,差异有统计学意义(P<0.05)。观察组患者临床症状体征改善时间明显短于对照组,差异均有统计学意义(P<0.05)。观察组患者致病菌清除率明显高于对照组,差异有统计学意义(P<0.05)。结论头孢哌酮舒巴坦钠治疗CAP临床疗效满意,致病菌清除率高,安全可靠,值得临床推广应用。
Objective To observe the clinical efficacy of cefoperazone sulbactam sodium in the treatment of community-acquired pneumonia (CAP). Methods 80 CAP patients were randomly divided into observation group and control group, 40 cases each. The observation group was treated with cefoperazone sulbactam sodium, while the control group was treated with levofloxacin. The clinical curative effect, the improvement of symptoms and signs and the clearance of pathogenic bacteria were compared between the two groups. Results After 7 days of treatment, the total effective rate in the observation group was 95.00%, which was significantly higher than that in the control group (92.25%) (P <0.05). The improvement time of clinical symptoms and signs in the observation group was significantly shorter than that in the control group, with significant differences (P <0.05). The clearance rate of pathogenic bacteria in observation group was significantly higher than that in control group, the difference was statistically significant (P <0.05). Conclusions Cefoperazone sulbactam sodium is effective in treating CAP, its pathogenic bacteria clearance rate is high, safe and reliable, which is worthy of clinical application.